Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Gains Rights to Korean Cancer mAb for Emerging Countries

publication date: Nov 19, 2014
3SBio of Shenyang has in-licensed rights to Tanibirumab, a cancer antibody developed by PharmAbcine, a Korean biotech. Tanibirumab is a VEGFR2/KDR antibody with an anti-angiogenesis mechanism. 3SBio will own rights to the molecule for Greater China and emerging countries Thailand, Brazil and Russia. PharmAbcine was spun out of the Korea Research Institute of Bioscience and Biotechnology, a government-backed organization. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital